{"success":true,"data":{"pressRelease":{"id":"171961","rtpr_id":"nGNX9zTV3z-20261018","ticker":"EIKN","exchange":"NASDAQ","all_tickers":["EIKN"],"title":"Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress","author":"Globe Newswire","published_at":"2026-10-18T22:05:00.101Z","article_body":"Presentations to cover updates across Eikon’s clinical pipeline including: \n* Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of\nEIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate\nchemotherapy in stage 4 non-small cell lung cancer (NSCLC)\n* Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly\nselective non-brain penetrant PARP1 inhibitor, as monotherapy and in\ncombination with chemotherapy in advanced solid tumors\n* Initial data from a Phase 1/2 study of EIK1003 in combination with the novel\nhormonal agent abiraterone in metastatic prostate cancer\n* Initial results from an ongoing Phase 1/2 study of EIK1004, a highly\nselective CNS-penetrant PARP1 inhibitor in advanced solid malignancies\n* Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a\nWerner (WRN) helicase inhibitor\nMILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc.\n(Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company\ndedicated to developing innovative medicines to address serious unmet medical\nneeds, today announced the publication of full-text abstracts from its four\nclinical candidates to be presented at the 2026 European Society for Medical\nOncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026.\n\n“We are looking forward to sharing updates from across our pipeline at ESMO,\nwith seven abstracts highlighting both new clinical findings, and continued\nprogress in our oncology programs,” said Roger M. Perlmutter, M.D., Ph.D.,\nChief Executive Officer and Board Chair of Eikon. “Eikon scientists and\nclinicians look forward to discussing these results with the broader oncology\ncommunity in Spain.”\n\n2026 ESMO Abstract Titles and Presentation Details:\n\nEIK1001\n\nTitle: 2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist)\nplus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results\nfrom the squamous cohort and updated pooled results\nDate: Monday, October 26, 2026\nTime: 12:00 - 12:45\n\nTitle: 2724TiP - A Phase 2/3 Study of EIK1001 in Combination with\nPembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell\nLung Cancer (NSCLC) [TeLuRide-008]\nDate: Monday, October 26, 2026\nTime: 12:00 - 12:45\n\nEIK1003\n\nTitle: 1048P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as\nmonotherapy and in combination with paclitaxel (PTX) in advanced solid tumors\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nTitle: 1049P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in\ncombination with abiraterone in patients with metastatic prostate cancer (mPC)\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nEIK1004\n\nTitle: 1060P - A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective\nCNS-penetrant inhibitor, in patients with advanced solid tumors with HRR\nmutations\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nEIK1005\n\nTitle: 1143eTiP - Phase 1/2 Study of the Novel Werner Helicase Inhibitor\nEIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with\nAdvanced Solid Tumors, Including MSI-H or dMMR Tumors\nePoster\n\nTitle: 1010P - Analysis of the Safety, Tolerability, and PK of EIK1005, a\nNovel WRN Inhibitor\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nAbout Eikon Therapeutics\nEikon is a late-stage clinical biopharmaceutical company dedicated to building\na global, fully-integrated organization developing innovative medicines to\naddress serious unmet medical needs. Eikon’s initial focus is oncology,\nwhere it is advancing a pipeline of drug candidates targeting areas of high\nunmet need that could eventually become critical medicines for the treatment\nof various cancers. Eikon deploys its technology platform, including its\nproprietary single molecule tracking system, to develop internally-derived\nnovel therapies, while also leveraging the deep expertise of its management\nteam to in-license promising assets. Eikon’s vision is to become a\ngenerational leader, by purposefully integrating traditional biology research\nwith advanced engineering to develop better medicines faster. For more\ninformation, visit www.eikontx.com.\n\nForward-Looking/Safe Harbor Statements\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995. All statements in this press release that are not historical\nfacts are hereby identified as forward-looking statements for this purpose.\nThese statements may be identified by words such as “aims,”\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “forecasts,” “goal,” “intends,” “may,”\n“plans,” “possible,” “potential,” “seeks,” “will” and\nvariations of these words or similar expressions that are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. Forward-looking statements in this press release include,\nbut are not limited to, statements regarding: the therapeutic potential,\nsafety, and efficacy of Eikon’s product candidates; the timing for\nanticipated data readouts; expected milestones and business objectives for\n2026 and beyond, including Eikon’s anticipated presentations at the 2026\nESMO Congress; and other statements regarding Eikon’s future operations,\nfinancial performance, financial position, prospects, objectives, strategies\nand other future events.\n\nThese forward-looking statements are based upon management’s current\nexpectations and assumptions, and are subject to a number of risks,\nuncertainties and other factors that could cause actual results and events to\ndiffer materially and adversely from those indicated by such forward-looking\nstatements including, among others: our limited operating history; our\nsignificant net losses incurred since inception and the likelihood of\nincurring additional losses for the foreseeable future; our need for\nsubstantial additional funding; the early stage of development of many of our\nproduct candidates and the possibility that our product candidates may fail in\ndevelopment; our dependence on the success of our current product candidates;\nour ability to leverage our technology platform to enable more informed drug\nresearch and development; legal and regulatory risks; intellectual\nproperty-related risks; and those risks, uncertainties and other factors\ndiscussed under the caption “Risk Factors” and elsewhere in Eikon’s\nQuarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with\nthe Securities and Exchange Commission (“SEC”) on August 13, 2026, and in\nother public filings with the SEC in the future.\n\nAs a result, you should not place undue reliance on any forward-looking\nstatements. The forward-looking statements made in this press release speak\nonly as of the date of this press release, and Eikon undertakes no obligation\nto update such forward-looking statements, whether as a result of new\ninformation, future developments or otherwise, except as required by law.\n\nContacts:\n\nInvestors\nAlfred “Freddie” Bowie, Ph.D., CFO\nir@eikontx.com\n\nMedia\nColin Sanford\ncolin@bioscribe.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9zTV3z-20261018","title":"Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress","author":"Globe Newswire","ticker":"EIKN","created":"2026-10-18T22:05:00.101Z","tickers":["EIKN"],"exchange":"NASDAQ","article_body":"Presentations to cover updates across Eikon’s clinical pipeline including: \n* Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of\nEIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate\nchemotherapy in stage 4 non-small cell lung cancer (NSCLC)\n* Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly\nselective non-brain penetrant PARP1 inhibitor, as monotherapy and in\ncombination with chemotherapy in advanced solid tumors\n* Initial data from a Phase 1/2 study of EIK1003 in combination with the novel\nhormonal agent abiraterone in metastatic prostate cancer\n* Initial results from an ongoing Phase 1/2 study of EIK1004, a highly\nselective CNS-penetrant PARP1 inhibitor in advanced solid malignancies\n* Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a\nWerner (WRN) helicase inhibitor\nMILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc.\n(Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company\ndedicated to developing innovative medicines to address serious unmet medical\nneeds, today announced the publication of full-text abstracts from its four\nclinical candidates to be presented at the 2026 European Society for Medical\nOncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026.\n\n“We are looking forward to sharing updates from across our pipeline at ESMO,\nwith seven abstracts highlighting both new clinical findings, and continued\nprogress in our oncology programs,” said Roger M. Perlmutter, M.D., Ph.D.,\nChief Executive Officer and Board Chair of Eikon. “Eikon scientists and\nclinicians look forward to discussing these results with the broader oncology\ncommunity in Spain.”\n\n2026 ESMO Abstract Titles and Presentation Details:\n\nEIK1001\n\nTitle: 2664P - TeLuRide-005: Phase 2 study of EIK1001 (TLR7/8 dual agonist)\nplus pembrolizumab and chemotherapy in patients with stage IV NSCLC: results\nfrom the squamous cohort and updated pooled results\nDate: Monday, October 26, 2026\nTime: 12:00 - 12:45\n\nTitle: 2724TiP - A Phase 2/3 Study of EIK1001 in Combination with\nPembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell\nLung Cancer (NSCLC) [TeLuRide-008]\nDate: Monday, October 26, 2026\nTime: 12:00 - 12:45\n\nEIK1003\n\nTitle: 1048P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, as\nmonotherapy and in combination with paclitaxel (PTX) in advanced solid tumors\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nTitle: 1049P - Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in\ncombination with abiraterone in patients with metastatic prostate cancer (mPC)\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nEIK1004\n\nTitle: 1060P - A first-in-human Phase 1/2 study of EIK1004, a PARP1-selective\nCNS-penetrant inhibitor, in patients with advanced solid tumors with HRR\nmutations\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nEIK1005\n\nTitle: 1143eTiP - Phase 1/2 Study of the Novel Werner Helicase Inhibitor\nEIK1005 as Monotherapy and in Combination with Pembrolizumab in Patients with\nAdvanced Solid Tumors, Including MSI-H or dMMR Tumors\nePoster\n\nTitle: 1010P - Analysis of the Safety, Tolerability, and PK of EIK1005, a\nNovel WRN Inhibitor\nDate: Friday, October 23, 2026\nTime: 15:15 - 16:00\n\nAbout Eikon Therapeutics\nEikon is a late-stage clinical biopharmaceutical company dedicated to building\na global, fully-integrated organization developing innovative medicines to\naddress serious unmet medical needs. Eikon’s initial focus is oncology,\nwhere it is advancing a pipeline of drug candidates targeting areas of high\nunmet need that could eventually become critical medicines for the treatment\nof various cancers. Eikon deploys its technology platform, including its\nproprietary single molecule tracking system, to develop internally-derived\nnovel therapies, while also leveraging the deep expertise of its management\nteam to in-license promising assets. Eikon’s vision is to become a\ngenerational leader, by purposefully integrating traditional biology research\nwith advanced engineering to develop better medicines faster. For more\ninformation, visit www.eikontx.com.\n\nForward-Looking/Safe Harbor Statements\nThis press release contains forward-looking statements within the meaning of\nthe “safe harbor” provisions of the Private Securities Litigation Reform\nAct of 1995. All statements in this press release that are not historical\nfacts are hereby identified as forward-looking statements for this purpose.\nThese statements may be identified by words such as “aims,”\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “forecasts,” “goal,” “intends,” “may,”\n“plans,” “possible,” “potential,” “seeks,” “will” and\nvariations of these words or similar expressions that are intended to identify\nforward-looking statements, although not all forward-looking statements\ncontain these words. Forward-looking statements in this press release include,\nbut are not limited to, statements regarding: the therapeutic potential,\nsafety, and efficacy of Eikon’s product candidates; the timing for\nanticipated data readouts; expected milestones and business objectives for\n2026 and beyond, including Eikon’s anticipated presentations at the 2026\nESMO Congress; and other statements regarding Eikon’s future operations,\nfinancial performance, financial position, prospects, objectives, strategies\nand other future events.\n\nThese forward-looking statements are based upon management’s current\nexpectations and assumptions, and are subject to a number of risks,\nuncertainties and other factors that could cause actual results and events to\ndiffer materially and adversely from those indicated by such forward-looking\nstatements including, among others: our limited operating history; our\nsignificant net losses incurred since inception and the likelihood of\nincurring additional losses for the foreseeable future; our need for\nsubstantial additional funding; the early stage of development of many of our\nproduct candidates and the possibility that our product candidates may fail in\ndevelopment; our dependence on the success of our current product candidates;\nour ability to leverage our technology platform to enable more informed drug\nresearch and development; legal and regulatory risks; intellectual\nproperty-related risks; and those risks, uncertainties and other factors\ndiscussed under the caption “Risk Factors” and elsewhere in Eikon’s\nQuarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with\nthe Securities and Exchange Commission (“SEC”) on August 13, 2026, and in\nother public filings with the SEC in the future.\n\nAs a result, you should not place undue reliance on any forward-looking\nstatements. The forward-looking statements made in this press release speak\nonly as of the date of this press release, and Eikon undertakes no obligation\nto update such forward-looking statements, whether as a result of new\ninformation, future developments or otherwise, except as required by law.\n\nContacts:\n\nInvestors\nAlfred “Freddie” Bowie, Ph.D., CFO\nir@eikontx.com\n\nMedia\nColin Sanford\ncolin@bioscribe.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/02bfb0a7-27fe-4be6-b2f9-bc6eaf27b1d9)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-18T22:05:00.143037901Z","server_sent_at_ms":1792361100143},"received_at":"2026-10-18T22:05:00.722Z","source_url":null},"analysis":{"id":"160107","press_release_id":"171961","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Eikon Therapeutics announced availability of seven abstracts covering its four clinical candidates for presentation at the 2026 ESMO Congress in Madrid beginning October 23.\n\nThe presentations include updated TeLuRide-005 Phase 2 data for EIK1001 in stage 4 NSCLC, Phase 1/2 data for the PARP1 inhibitors EIK1003 and EIK1004, and preliminary safety/PK data for the WRN helicase inhibitor EIK1005.\n\nNo new results are included in this release; the actual data readouts at ESMO are the potential catalyst for the stock.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Pre-read for ESMO data drops across four oncology candidates starting Oct 23 -- watch for EIK1001 NSCLC cohort updates as the key readout."},"keyFigures":{"drugName":"EIK1001, EIK1003, EIK1004, EIK1005","phaseOfTrial":"Phase 1/2 and Phase 2","customDimensions":{"abstract_count":7}},"quotedText":"We are looking forward to sharing updates from across our pipeline at ESMO, with seven abstracts highlighting both new clinical findings, and continued progress in our oncology programs","namedEntities":{"people":[{"name":"Roger M. Perlmutter, M.D., Ph.D.","role":"CEO and Board Chair"},{"name":"Alfred \"Freddie\" Bowie, Ph.D.","role":"CFO"},{"name":"Colin Sanford","role":"media contact"}],"products":["EIK1001","EIK1003","EIK1004","EIK1005","pembrolizumab","abiraterone","TeLuRide-005","TeLuRide-008"],"companies":[{"name":"Eikon Therapeutics, Inc.","ticker":"EIKN"},{"name":"European Society for Medical Oncology","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Announcement of upcoming ESMO abstract presentations and conference availability; no new clinical data, endpoints, or results are disclosed in the release itself. Data readouts occur at the congress beginning October 23, 2026."},"tickerRelevance":{"others":[],"primary":"EIKN"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-abstract-availability-no-data","sectorWeight":"biotech-ESMO-catalyst-pre-read","issuerAuthored":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Eikon Therapeutics announced availability of seven abstracts covering its four clinical candidates for presentation at the 2026 ESMO Congress in Madrid beginning October 23.\n\nThe presentations include updated TeLuRide-005 Phase 2 data for EIK1001 in stage 4 NSCLC, Phase 1/2 data for the PARP1 inhibitors EIK1003 and EIK1004, and preliminary safety/PK data for the WRN helicase inhibitor EIK1005.\n\nNo new results are included in this release; the actual data readouts at ESMO are the potential catalyst for the stock.","key_figures":{"drugName":"EIK1001, EIK1003, EIK1004, EIK1005","phaseOfTrial":"Phase 1/2 and Phase 2","customDimensions":{"abstract_count":7}},"named_entities":{"people":[{"name":"Roger M. Perlmutter, M.D., Ph.D.","role":"CEO and Board Chair"},{"name":"Alfred \"Freddie\" Bowie, Ph.D.","role":"CFO"},{"name":"Colin Sanford","role":"media contact"}],"products":["EIK1001","EIK1003","EIK1004","EIK1005","pembrolizumab","abiraterone","TeLuRide-005","TeLuRide-008"],"companies":[{"name":"Eikon Therapeutics, Inc.","ticker":"EIKN"},{"name":"European Society for Medical Oncology","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-18T22:05:05.222Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-abstract-availability-no-data","sectorWeight":"biotech-ESMO-catalyst-pre-read","issuerAuthored":true}},"durationMs":4489,"modelName":"glm-5.3-flashx"}}